Allergy Therapeutics plc
("Allergy Therapeutics", "ATL" or the "Group")
Total Voting Rights and Block Listing Return
Allergy Therapeutics plc (AIM: AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, announces that pursuant to its block admission facility, details of which were announced on 21 November 2017, it has recently issued 401,850 ordinary shares of 0.1 pence each ("Ordinary Shares") in satisfaction of the exercise of share options. The new Ordinary Shares rank pari passu with the Company's existing shares.
In accordance with DTR 5.6.1 of the Financial Conduct Authority's Disclosure Guidance and Transparency Rules, as at 31 January 2022, the Company had 643,998,996 Ordinary Shares in issue. There are no shares held in treasury. The total number of voting rights in the Company is therefore 643,998,996.
The above figure of 643,998,996 may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.
Block Listing Return
Allergy also makes the following notification pursuant to AIM Rule 29 and Schedule Six of the AIM Rules for Companies, regarding its existing block listing (excluding the additional block listing applications above and those block listings that have now been cancelled):
|
Name of applicant: |
ALLERGY THERAPEUTICS PLC |
|||
|
Name of scheme: |
Allergy Therapeutics plc 2013 Long Term Incentive Plan |
|||
|
Period of return: |
From: |
31 January 2021 |
To: |
31 January 2022 |
|
Number and class of share(s) (amount of stock / debt securities) originally listed and the date of admission: |
10,000,000 ordinary shares of 0.1p each in the Company admitted to trading on 24 November 2017 |
|||
|
Balance of unallotted securities under scheme(s) from previous return: |
3,325,604
|
|||
|
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): |
7,000,000 |
|||
|
Less: Number of securities issued/allotted under scheme(s) during period: |
3,206,832 |
|||
|
Equals: Balance under scheme(s) not yet issued/allotted at end of period: |
7,118,772 |
|||
|
Name of contact: |
Sara Goldsbrough |
|
Telephone number of contact: |
+44 (0) 7966 165719 |
For further information, please contact:
Allergy Therapeutics
+44 (0) 1903 845 820
Manuel Llobet, Chief Executive Officer
Nick Wykeman, Chief Financial Officer
Panmure Gordon
+44 (0) 20 7886 2500
Freddy Crossley, Emma Earl, Corporate Finance
Rupert Dearden, Corporate Broking
Consilium Strategic Communications
+44 20 3709 5700
Mary-Jane Elliott / David Daley / Davide Salvi
allergytherapeutics@consilium-comms.com
Stern Investor Relations, Inc.
+1 212 362 1200
Christina Tartaglia
Notes for editors:
About Allergy Therapeutics
Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third-party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development includes vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development. Adjuvant systems to boost performance of vaccines outside allergy are also in development.
Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics is headquartered in Worthing, UK with more than 11,000m2 of state-of-the-art MHRA-approved manufacturing facilities and laboratories. The Group, which has achieved over 9% compound annual growth since formation, employs c.600 employees and is listed on the London Stock Exchange (AIM:AGY). For more information, please see www.allergytherapeutics.com .
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
